CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) recently granted equity inducement awards to 12 new non-executive employees on April 1, 2026, under its 2025 Inducement Plan.
The awards, approved by the company’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4), were issued as an inducement for employment.
The employees received a total of 5,758 time-based restricted stock units.
The restricted stock units vest in four equal installments on each of the first through fourth anniversaries of the grant date, subject to continued employment.
Madrigal Pharmaceuticals develops treatments for metabolic dysfunction-associated steatohepatitis, a liver disease.
The company’s drug Rezdiffra (resmetirom) is approved by the U.S. Food and Drug Administration and the European Commission for the treatment of MASH with moderate to advanced fibrosis.
An ongoing Phase 3 trial is evaluating the drug for patients with compensated MASH cirrhosis.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.